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A single early prostate-specific antigen (PSA) level has been correlated with a higher 
likelihood of prostate cancer diagnosis and death in younger men. PSA testing in older 
men has been considered of limited utility. We evaluated prostate cancer death in relation 
to age and PSA level immediately prior to prostate cancer diagnosis. Using the Veterans 
Affairs database, we identified 230,081 men aged 50–89 years diagnosed with prostate 
cancer and at least one prior PSA test between 1999 and 2009. Prostate cancer-specific 
death over time was calculated for patients stratified by age group (e.g., 50–59 years, 
through 80–89  years) and PSA range at diagnosis (10 ranges) using Kaplan–Meier 
methods. Risk of 10-year prostate cancer mortality across age and PSA was compared 
using log-rank tests with a Bonferroni adjustment for multiple testing. 10.5% of men 
diagnosed with prostate cancer died of cancer during the 10-year study period (mean 
follow-up =  3.7  years). Higher PSA values prior to diagnosis predict a higher risk of 
death in all age groups (p < 0.0001). Within the same PSA range, older age groups are 
at increased risk for death from prostate cancer (p < 0.0001). For PSA of 7–10 ng/mL, 
cancer-specific death, 10 years after diagnosis, increased from 7% for age 50–59 years 
to 51% for age 80–89 years. Men older than 70 years are more likely to die of prostate 
cancer at any PSA level than younger men, suggesting prostate cancer remains a signif-
icant problem among older men (even those aged 80+) and deserves additional study.
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inTrODUcTiOn
Each year, prostate cancer claims the lives of nearly 307,000 men worldwide and nearly 30,000 
men in the United States (1). The prostate cancer death rate in the United States has been nearly 
halved since the beginning of prostate-specific antigen (PSA)-based screening over 25 years ago 
(2). However, the benefits of PSA screening, and hence the PSA test itself, have been debated 
recently after the European Randomized Study of Screening for Prostate Cancer (ERSPC) (3) and 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) in the United States (4) 
revealed conflicting evidence about the benefit of PSA screening.
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The controversy about PSA screening implicitly questions 
the importance of diagnosing and treating prostate cancer. 
Understanding the magnitude of prostate cancer death, and 
which men are at higher risk of death, may identify those who 
could benefit from treatment. PSA level and older age prior to 
biopsy have independently been identified as risk factors for 
prostate cancer diagnosis, but their relationship with prostate 
cancer death has not been adequately addressed in the literature.
Stephenson et  al., in a multi-institutional study, demon-
strated that a higher PSA prior to surgical treatment leads to a 
higher risk of cancer-related death at 10 years, with the risk of 
death from prostate cancer doubling if the pretreatment PSA 
increases from <4 ng/mL to 10.1–20 ng/mL (5). However, this 
study did not consider age and was limited to only patients who 
underwent surgery, which is typically a healthy subset of men. 
A baseline or early PSA test result in younger men has been 
demonstrated in many studies to correlate with the likelihood of 
prostate cancer diagnosis (6–10) during their lifetime, and even 
likelihood of developing metastases (8) and prostate cancer-
specific death (8, 10–12).
These baseline and early PSA studies did not address whether 
patients should have a biopsy, though several risk calculators 
attempt to inform that decision. The ERSPC risk calculator 
estimates the probability a biopsy will find prostate cancer as a 
function of prior PSA and other variables but not age (13–15). 
The Prostate Cancer Prevention Trial (PCPT) risk calculator, on 
the other hand, estimates the probability of detecting prostate 
cancer with a biopsy as a function of age, prior PSA, and other 
variables – with the probability of a cancer diagnosis increasing 
as PSA and age prior to biopsy rise (16–19).
The increasing risk of a cancer diagnosis with age is likely to be 
offset, to some extent, by a reduced life expectancy for older men 
who may die of other causes before prostate cancer. Furthermore, 
over the last 50 years, there has been a steady decline in cardiac-
related death, the most common killer of Americans, and life 
expectancy continues to increase. The age-adjusted death rate 
from cardiovascular disease decreased almost 50% between 1963 
and 2010, even between 1990 and 2010, a 20% decrease was noted 
(20). With an increasingly healthy and older population, prostate 
cancer may become a more relevant cause of death. None of the 
published literature has estimated the risk of prostate cancer 
death for men diagnosed with prostate cancer as a function of 
age and PSA prior to biopsy for any population, whether small 
or large. An understanding of the risk of cancer death, not just 
the likelihood of cancer detection, could inform the decision for 
older men whether to proceed to a biopsy.
In order to more clearly understand the magnitude of prostate 
cancer death in an aging population, we sought to evaluate the 
relationship between age and PSA prior to biopsy with the risk of 
subsequent prostate cancer death in a large national population 
of men diagnosed with prostate cancer.
MaTerials anD MeThODs
Participants and Data sets
This is a cohort study of 230,081 men aged 50–89  years diag-
nosed with prostate cancer in the Veterans Administration (VA) 
between 1999 and 2009. The goal of the study is to determine 
the risk of prostate cancer death during this 10-year time period 
according to age and PSA level at diagnosis. Data for this study 
were compiled from all VA facilities across the United States, 
available in the corporate data warehouse (CDW). Men diag-
nosed with prostate cancer were identified by (1) a diagnosis code 
in the patient record or (2) a surgery code in the patient record 
for men with no diagnosis code. Diagnosis date was determined 
to be the earliest date of diagnosis found in one of four sources 
where the International Classification of Diseases 9th edition 
(ICD-9) code of 185 appeared: the VA Central Cancer Registry 
data file; the CDW outpatient table; the CDW inpatient table; or 
the Surgical Quality Data Use Group (SQDUG) data file. PSA test 
values were identified by the presence of a Logical Observation 
Identifiers Names and Codes (LOINC) code 2857-1 in the CDW 
Patient Laboratory Chemistry (LabChem) table. When available, 
numeric values were used for PSA test results. In the absence of 
a numeric value, the text was parsed and analyzed to identify a 
PSA test result. Duplicate PSA values were purged. The PSA test 
result immediately prior to diagnosis was used as the PSA value 
at diagnosis. The VA vital status mini table of the CDW provided 
patient demographics, including date of birth, which was used to 
determine age at the time of prostate cancer diagnosis. Within 
the VA dataset, the variables that were high quality and useable 
in this analysis were limited to PSA, age, and diagnosis of prostate 
cancer.
cancer-specific Death
Our main outcome variable was prostate cancer death between 
January 1, 1999 and December 31, 2009. This was the period 
for which National Death Index (NDI) cause of death data were 
available. For patients with an indication of death and year of 
death, the cause of death from prostate cancer was determined 
using the presence of the ICD-9 code 185 (used before 1999) or 
the ICD-10 code C61 (used after 1998). The NDI was previously 
validated in a chart review by Warren et al. who found a greater 
than 96% accuracy of the cause of death (21).
statistical analyses
The men in our cohort included those who received no treatment, 
androgen deprivation alone, radiation alone, surgery, and combi-
nation therapies. The study population was categorized into one 
of the four age groups: 50–59, 60–69, 70–79, and 80–89  years. 
Men were grouped into 10 PSA ranges at diagnosis: 3–4.9, 5–6.9, 
7–9.9, 10–14, 15–19, 20–39, 50–59, 60–99, 100–199, and 200+. 
For each group, the percentage of men who died of cancer was 
calculated. The Cochran–Armitage test (22) for trends was used 
for PSA and for age for various PSA ranges. Cancer-specific death 
over time was calculated for each combination of age group and 
PSA range using Kaplan–Meier methods (23). We performed 
log-rank analysis of differences among PSA ranges for each of the 
four age groups as well as differences among age groups for each 
of the 10 PSA ranges. (R version 3.2.1) Multiple hypothesis testing 
calls for consideration of the conservative family-wise error rate 
(FWER) or the false discovery rate (FDR). For simplicity, we 
used the most conservative Bonferroni FWER procedure (24) to 
adjust the p-values for multiple tests. To compare cancer-specific 
TaBle 1 | Patient demographics and characteristics at diagnosis and cancer death.
age at diagnosis
number of men Overall 50–59 60–69 70–79 80–89
Diagnosed (% of total) 230,081 (100) 32,386 (15) 70,863 (32) 88,051 (36) 38,781 (17)
Died of PCa (% of total) 24,142 (100) 1,371 (6) 4,091 (17) 10,553 (44) 8,127 (34)
Men diagnosed – prostate cancer
Age at diagnosis
Mean 70.7 56.5 65.2 75.0 83.6
Median (IQR) 72.2 (14.4) 57.5 (4.0) 66.2 (5.1) 74.5 (4.7) 82.5 (3.9)
PSA
Mean 26.4 19.0 18.9 24.4 51.8
Median (IQR) 5.3 (6.9) 5.2 (5.1) 5.3 (5.2) 5.3 (7.7) 6.2 (13.7)
Follow-up
Mean 3.7 4.1 3.8 3.8 2.8
Median (IQR) 3.3 (4.2) 3.8 (4.3) 3.3 (4.5) 3.4 (4.1) 2.3 (3.2)
Men died – prostate cancer
Age at diagnosis
Mean 75.5 56.3 65.8 75.6 83.8
Median (IQR) 77.1 (10.5) 56.8 (4.0) 66.6 (4.7) 76.3 (4.6) 83.1 (4.4)
PSA
Mean 146.2 218.3 165.0 119.8 159.5
Median (IQR) 12.4 (44.3) 16.4 (84.9) 11.5 (45.6) 10.6 (34.6) 14.9 (51.8)
Follow-up
Mean 2.8 2.8 3.1 3.1 2.3
Median (IQR) 2.3 (3.2) 2.1 (3.0) 2.5 (3.5) 2.5 (3.4) 1.8 (2.6)
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death across the PSA ranges for each of the four age groups, we 
multiplied each p-value by the four tests being performed. To 
compare cancer-specific death across the age groups for each of 
the 10 PSA ranges, we multiplied each p-value by the 10 tests 
being performed. Cancer-specific deaths after diagnosis during 
the 10  years of the study period (1999–2009) were graphed as 
a function of PSA at diagnosis for each age range separately. 
Receiver operator characteristic (ROC) curves were created (R 
version 3.2.1) to determine the discrimination of PSA level and 
age at diagnosis on prostate cancer death and a simple linear 
combination of the two (PSA + 1.2 × age) in predicting a higher 
risk of prostate cancer mortality. On average, we observed that 
1.2 years of age had approximately the same influence as 1.0 unit 
of PSA. For each age group, areas under the curve (AUC) were 
calculated for PSA level at diagnosis to determine if PSA levels are 
similarly predictive of prostate cancer death with advancing age.
resUlTs
Population characteristics
Patient characteristics for the 230,081 men aged 50–89  years 
diagnosed with prostate cancer between 1999 and 2009 are shown 
in Table  1. For the 10-year study period, mean follow-up was 
3.7 years. The mean age at diagnosis was 70.7 years (median 72.2). 
For the men who died of prostate cancer within the study period, 
the mean age at diagnosis was 75.5 years (median 77.1). Mean 
PSA at diagnosis was higher for men aged 70–89  years (mean 
PSA = 33.3) than men aged 50–69 years (mean PSA = 19.0). Mean 
and median PSA values at diagnosis were substantially higher for 
the men who died of prostate cancer, both overall and within each 
age group. In contrast, mean PSA at death was independent of age 
among the men who died of prostate cancer (mean PSA = 146.2 
with no age trend).
cancer-specific Death rates
A total of 24,142 (10.5%) of the men in our cohort died of prostate 
cancer between 1999 and 2009. The numbers of men who were 
diagnosed with and then died of prostate cancer are shown in 
Table 2 and are stratified by age group and PSA range. Of men 
who died of prostate cancer, 54.6% were diagnosed at PSA values 
of 10 or higher, and 77.4% were diagnosed at age 70 or older. 
Across all age groups, the percentage of men who died of prostate 
cancer increased as PSA at diagnosis increased (p < 0.0001 for 
trend). For PSA 0–10, the percentage of men who died of prostate 
cancer increased with increasing age (p < 0.0001 for trend).
Higher PSA values at diagnosis predict a higher risk of 
cancer-specific death in all age groups as shown in Figure 1. The 
log-rank test with conservative Bonferroni adjustments to the 
p-values yields p <  0.0001 for all four age ranges. In addition, 
older age groups have an increasing risk of death for the same 
PSA range with the largest percentage differences at the lowest 
PSA ranges (test-adjusted log-rank p < 0.0001 for all ranges of 
PSA). In Figure 2, we plotted the actuarial 10-year death rates 
from Figure 1 as a function of PSA for each age group. The higher 
cancer-specific death at older ages is seen even at low PSA levels, 
and this difference in mortality remains at higher levels of PSA.
PSA and age at diagnosis are strong independent predictors of 
prostate cancer death compared to no cancer death but are more 
predictive in combination. The AUCs for the ROC curves were 
0.79 for the simple linear function of PSA and age, 0.72 for PSA 
alone, and 0.67 for age alone, as shown in Figure 3. The AUC for 
PSA alone was 0.77, 0.73, 0.71, and 0.71 for ages 50–59, 60–69, 
70–79, and 80–89 years, respectively.
FigUre 1 | cancer-specific death after diagnosis by age and Psa at 
diagnosis. For all men aged 50–59 years (a), 60–69 years (b), 70–79 years 
(c), and 80–89 years (d) diagnosed with prostate cancer, cancer-specific 
death risk is plotted as a function of time elapsed from diagnosis (years) for 
various ranges of prostate-specific antigen (PSA) levels at diagnosis.
TaBle 2 | Distributions of age and Psa at diagnosis for diagnosed men 
and cancer deaths.
age at diagnosis
Overall 50–59 60–69 70–79 80–89
number of men diagnosed with prostate cancer vs. Psa at diagnosis
Psa (ng/ml)
0–2.9 70,836 8,761 19,112 28,881 14,082
3–4.9 40,912 7,292 15,039 14,200 4,381
5–9.9 67,512 10,729 24,432 25,049 7,302
10–19.9 27,323 3,333 7,419 10,984 5,587
20–49.9 13,217 1,385 2,884 5,094 3,854
50–99.9 4,434 405 840 1,676 1,513
≥100 5,847 481 1,137 2,167 2,062
Total 230,081 32,386 70,863 88,051 38,781
number of men died of prostate cancer (% of diagnosed in category)
Psa (ng/ml)
0–2.9 4,467 (6) 171 (2) 629 (3) 1,980 (7) 1,687 (12)
3–4.9 2,203 (5) 112 (2) 414 (3) 1,023 (7) 654 (15)
5–9.9 3,301 (6) 263 (2) 855 (3) 2,043 (8) 1,140 (16)
10–19.9 3,749 (14) 181 (5) 618 (8) 1,710 (16) 1,240 (22)
20–49.9 3,553 (27) 196 (14) 545 (19) 1,490 (29) 1,322 (34)
50–99.9 1,933 (44) 128 (32) 306 (36) 805 (48) 694 (46)
≥100 3,936 (67) 320 (67) 724 (64) 1,502 (69) 1,390 (67)
Total 24,142 (10) 1,371 (4) 4,091 (6) 10,553 (12) 8,127 (21)
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DiscUssiOn
While many studies, calculators, and nomograms have cor-
related PSA levels with a higher likelihood of detecting cancer, 
our study is the first national cohort study to demonstrate a 
correlation between pre-diagnosis PSA level and 10-year cancer-
specific death across increasingly older age groups, even among 
men 80+.
For example, the PCPT risk calculator estimates the probabil-
ity that a biopsy will detect cancer for individual men (16–19). 
For Caucasian men, aged 55  years, without other risk factors, 
the probability a biopsy will detect cancer increases from 18% 
at PSA 3.0 ng/mL to 29% at PSA 10.0 ng/mL. For similar men 
at age 75, the probability increases from 26% at PSA 3.0  ng/
mL to 42% at PSA 10.0  ng/mL, which suggests older men 
might benefit more from a biopsy than younger men. Using 
the findings of this study, that same older man, if diagnosed 
with prostate cancer when his PSA is 3, has a 23% chance of 
dying within 10  years from his prostate cancer, compared to 
a 33% chance of death if he is not diagnosed until his PSA 
is 10. While a diagnosis of prostate cancer is important, it is 
clearly recognized that not all prostate cancers are deadly. This 
is especially important when we consider screening older men 
as the increasing risk of cancer diagnosis with age is likely to be 
offset, to some extent, by reduced life expectancy for older men 
who may die of other causes before prostate cancer kills them. 
Utilizing PSA to understand and potentially predict the impact 
on a man’s survival is even more relevant than predicting the 
FigUre 3 | cancer-specific death rOc curves for age and Psa at 
diagnosis. Receiver operator characteristic (ROC) curves show the 
sensitivity to prostate cancer death and the specificity to no cancer death for 
the variables: PSA, age, and a simple linear combination of the two 
(PSA + 1.2 × age).
FigUre 2 | cancer-specific death at 10 years by age and Psa at diagnosis. Death risk from prostate cancer 10 years after diagnosis is plotted as a function 
of prostate-specific antigen (PSA) level at diagnosis (nanogram per milliliter) for men aged 50–59, 60–69, 70–79, and 80–89 years who were diagnosed with 
prostate cancer.
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presence of prostate cancer and could significantly inform the 
decision whether to biopsy older men, especially healthy ones 
with longer life expectancies.
Of men in this study who died of prostate cancer, 54.6% were 
diagnosed at high (>10 ng/mL) PSA levels, and 39.0% were diag-
nosed at very high PSA levels (>20 ng/mL). This suggests that 
some men were unscreened prior to diagnosis, which is consist-
ent with national screening rates at VA hospitals and clinics (25). 
It also shows that much of the death risk is associated with PSA 
levels at diagnosis substantially above the screening guidelines 
used in the past.
In our study population, 77% of prostate cancer deaths 
occurred in men diagnosed at age 70–89. This finding suggests 
that if we are going to reduce prostate cancer death substantially, 
we should reconsider the management of prostate cancer in older 
men, especially healthy men with longer life expectancies. The 
high proportion of all deaths concentrated in older men can 
be explained, in part, by the increasing risk of death with age 
for any PSA level. For example, for PSA in the 7–10 range, the 
cancer-specific death risk 10-years after diagnosis is only 7% for 
men aged 50–59 years, but 51% for men aged 80–89 years. This 
substantial upward shift in the risk of death at low PSA levels for 
older men results in a reduction in the overall increase in cancer 
death risk as PSA increases and may account for the reduction in 
the AUC for PSA alone as age increases with AUC of 0.77, 0.73, 
0.71, and 0.71 for ages 50–59, 60–69, 70–79, and 80–89 years, 
respectively.
Our finding that older men have increased cancer-specific 
mortality risk across all PSA ranges suggests that older men 
may be presenting with later-stage cancers, have cancers that 
behave more aggressively, and/or receive less aggressive treat-
ment than younger men. Findings of Tang et al. from the Duke 
Prostate Center Database (12) and a report by Aizer et al. that 
included men from the Surveillance, Epidemiology, and End 
Results Program (SEER) database with a median age of 67 years 
found older men diagnosed with low-risk prostate cancer had 
a higher cancer-specific death rate than younger men, whether 
they were observed or received treatment (26). Similarly, 
Scosyrev et  al. found that older patients who presented with 
prostate cancer had a higher incidence of metastatic disease at 
diagnosis (27).
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The current dogma that older men do not need treatment 
because of their age and comorbid conditions may need to give 
more weight to both their life expectancy and PSA level before 
diagnosis rather than age alone. For example, the average life 
expectancy for a 75-year-old man in United States is nearly 
12  years to age 87  years. If diagnosed at age 75 with a PSA of 
10, our results suggest that his risk of prostate cancer-specific 
death is likely to exceed 33% at his life expectancy, which may 
justify aggressive treatment. If his PSA reaches 40, his risk of 
prostate cancer-specific death is likely to exceed 65%. Clearly, 
many otherwise healthy older men diagnosed at elevated PSA 
levels will live long enough to die of prostate cancer with high 
to very high probabilities and may want to consider treatment 
options. A more detailed investigation of treatment in older men 
seems indicated to determine the cause of this high prostate 
cancer mortality rate and if any intervention could benefit these 
patients.
Recently identified problems with US National Cancer 
Institute SEER PSA data reporting (28) have raised questions 
about other large populations. In contrast to SEER, VA PSA 
data are a strength of our study because VA PSA values are 
extracted directly from VA clinical lab databases used for direct 
patient care.
There are several limitations to this study. It is an observational 
study that does not control for treatment and other variables. We 
also cannot determine if the PSA prior to the prostate cancer 
diagnosis was ordered for screening or diagnostic purpose, and 
the CDW does not include post-diagnosis prostate cancer clinical 
stage or grade information to identify men with more advanced 
disease at a given PSA. Mean follow-up time was 3.7  years, 
which is short for studies with small populations. In our study, 
the large group of men analyzed (230,081) allowed estimation of 
cancer-specific death for the full 10-year study period in spite of 
the short mean follow-up time.
cOnclUsiOn
PSA remains an important prognostic tool for prostate cancer 
death even at very advanced ages. Risk of death from prostate 
cancer directly correlates with the PSA level at diagnosis, 
and men older than 70  years have an increased risk of death 
from prostate cancer at all PSA levels, which can help inform 
decision-making.
The significant cancer-specific mortality rate in the elderly 
population, even at lower PSA values, suggests further study is 
needed about ways to decrease prostate cancer mortality in this 
often-understudied and perhaps underserved population.
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